UCB SA (OTCMKTS:UCBJY – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $93.61 and traded as high as $96.26. UCB shares last traded at $94.31, with a volume of 38,479 shares trading hands.
UCB Stock Down 3.6 %
The business has a 50 day moving average of $97.49 and a 200 day moving average of $93.61. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- Why Invest in 5G? How to Invest in 5G Stocks
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- Using the MarketBeat Dividend Tax Calculator
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
